跳至主要内容
临床试验/NCT06565910
NCT06565910
招募中
4 期

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for PENG Block on Post Operative Pain Management in Patients Undergoing Hip Arthroplasty: a Prospective, Randomized, Single Blind, Active Controlled Study

Huazhong University of Science and Technology1 个研究点 分布在 1 个国家目标入组 60 人2024年12月4日

概览

阶段
4 期
干预措施
Liposomal bupivacaine plus bupivacaine
疾病 / 适应症
Femoral Neck Fractures
发起方
Huazhong University of Science and Technology
入组人数
60
试验地点
1
主要终点
Overall Opioid Consumption
状态
招募中
最后更新
上个月

概览

简要总结

The goal of this clinical trial is to study the analgesic effect of liposomal bupivacaine plus bupivacaine for Pericapsular Nerve Group (PENG) block in postoperative pain management following hip replacement surgery. It will also assess the safety of liposomal bupivacaine for this purpose. The main questions it aims to answer are:

  1. Is liposomal bupivacaine plus bupivacaine superior to ropivacaine in terms of analgesic efficacy, duration of pain relief, opioid consumption, and patient satisfaction?
  2. What medical problems do participants encounter when using liposomal bupivacaine plus bupivacaine for PENG block in postoperative pain management following hip replacement surgery?

Researchers will compare liposomal bupivacaine plus bupivacaine to ropivacaine (a routinely used regional anesthetic in clinical practice) to determine if liposomal bupivacaine plus bupivacaine is more effective for pain management following hip replacement surgery.

Participants will:

  1. Receive liposomal bupivacaine plus bupivacaine or ropivacaine as a regional anesthetic for PENG block under ultrasound guidance.
  2. Undergo hip replacement surgery under spinal anesthesia.
  3. Have pain relief, opioid analgesic consumption, and incidence of complications assessed at multiple time points within 72 hours after surgery.
注册库
clinicaltrials.gov
开始日期
2024年12月4日
结束日期
2026年7月1日
最后更新
上个月
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Wei Mei

Clinical Professor

Huazhong University of Science and Technology

入排标准

入选标准

  • American Society of Anesthesiologists(ASA) I\~II
  • Normal coagulation
  • Clinical diagnosis of hip fracture

排除标准

  • Presence of severe systemic diseases or ASA grade III or higher
  • Allergy to amide local anesthetics

研究组 & 干预措施

Liposomal Bupivacaine plus Bupivacaine Intervention

Participants in this arm will receive liposomal bupivacaine(LB) plus bupivacaine(B) as a local anesthetic for PENG block under ultrasound guidance. Liposomal bupivacaine plus bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This arm aims to evaluate the analgesic efficacy, duration of pain relief, and safety profile of liposomal bupivacaine plus bupivacaine compared to the standard local anesthetic, ropivacaine. Participants in this arm will undergo hip replacement surgery under spinal anesthesia and will be assessed for pain relief, opioid analgesic consumption, and any associated complications at multiple time points within 72 hours after surgery.

干预措施: Liposomal bupivacaine plus bupivacaine

Ropivacaine Intervention

Participants in this arm will receive ropivacaine (R) as a local anesthetic for the PENG block under ultrasound guidance. Ropivacaine, a routinely used local anesthetic in clinical practice, is being compared to liposomal bupivacaine plus bupivacaine to assess its analgesic effect in postoperative pain management following hip replacement surgery. This arm aims to evaluate the analgesic efficacy, duration of pain relief, and safety profile of ropivacaine in comparison to the investigational intervention, liposomal bupivacaine. Participants in this arm will undergo hip replacement surgery under spinal anesthesia and will be assessed for pain relief, opioid analgesic consumption, and any associated complications at multiple time points within 72 hours after surgery.

干预措施: Ropivacaine

结局指标

主要结局

Overall Opioid Consumption

时间窗: this outcome will be monitored and recorded within 72 hours postoperatively

This primary outcome entails tracking and assessing the total opioid consumption by participants following hip replacement surgery. The evaluation includes quantifying the amount of opioids prescribed and consumed by participants for pain management post-surgery. Opioid medications administered will be converted to morphine equivalents based on established conversion ratios. By analyzing overall opioid consumption, the study aims to evaluate the efficacy of the interventions in managing postoperative pain.

次要结局

  • Time to First Rescue Analgesic(72 hours after surgery.)
  • Incidence of Complications or Adverse Events(90 days after the surgical procedure)
  • Pain intensity(at multiple time points within 72 hours post-surgery.)
  • Duration of Hospital Stay(through study completion, an average of 1 year)

研究点 (1)

Loading locations...

相似试验